TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid

Sørensen, Nanna Møller; Byström, Per; Christensen, Ib J.; Berglund, Åke; Nielsen, Hans Jørgen; Brünner, Nils; Glimelius, Bengt

Published in:
Clinical Cancer Research

DOI:
10.1158/1078-0432.CCR-07-0186

Publication date:
2007

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Sørensen, N. M., Byström, P., Christensen, I. J., Berglund, Å., Nielsen, H. J., Brünner, N., & Glimelius, B. (2007). TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clinical Cancer Research, 13(14), 4117-4122. DOI: 10.1158/1078-0432.CCR-07-0186
TIMP-1 Is Significantly Associated with Objective Response and Survival in Metastatic Colorectal Cancer Patients Receiving Combination of Irinotecan, 5-Fluorouracil, and Folinic Acid

Nanna M. Sørensen,¹ Per Bystro«m,² Ib J. Christensen,³ Åke Berglund,⁴ Hans Jørgen Nielsen,⁵ Nils Brünner,¹ and Bengt Glimelius²,⁴

Abstract

**Purpose:** Tissue inhibitor of metalloproteinase-1 (TIMP-1) is known to protect cells against apoptosis. We raised the hypothesis that elevated tumor tissue levels and thereby plasma levels of TIMP-1 would predict resistance to apoptosis-inducing chemotherapy.

**Experimental Design:** Ninety patients with metastatic colorectal cancer were included in the study. Plasma TIMP-1 and serum carcinoembryonic antigen (CEA) were measured in samples obtained before the first cycle of chemotherapy.

**Results:** Analysis of best objective response (complete or partial response versus stable or progressive disease) showed that patients with low plasma TIMP-1 had higher probability of obtaining an objective response [odds ratio (OR), 3.5; 95% confidence interval (95% CI), 1.4–8.5, *P* = 0.007]. CEA treated as a continuous variable was also a statistically significant predictor of no response (OR, 1.3; 95% CI, 1.0–1.7, *P* = 0.02, area under the curve 0.66) but much less so. Plasma TIMP-1 was the only significant covariate in a multivariable analysis of best objective response (OR, 3.6; 95% CI, 1.4–9.5; *P* = 0.001). Plasma TIMP-1 scored as a continuous variable on the log scale (logₐ) was significantly associated with overall survival (OS; hazard ratio (HR), 3.8; 95% CI, 2.4–5.9; *P* < 0.0001) and with time to progression (TTP; HR, 1.5; 95% CI, 1.0–2.3; *P* = 0.048). Multivariable analysis showed that plasma TIMP-1 was significant for OS when including routine clinical baseline covariates (HR, 3.5; 95% CI, 2.1–5.8; *P* < 0.0001). A multivariable analysis including TTP instead of OS showed that only plasma TIMP-1 was retained in the model (HR, 1.5).

CEA was not significantly associated with TTP or OS when TIMP-1 was included in the model.

**Conclusion:** This study shows that plasma TIMP-1 levels are significantly and independently associated with objective response, TTP, and OS in patients with metastatic colorectal cancer receiving combination chemotherapy.

In Europe and the United States, the number of new colorectal cancer cases approximates 500,000 on a yearly basis.⁵ Approximately half of the patients will develop metastatic colorectal cancer disease, and these patients are candidates for systemic chemotherapy. However, the objective response rate [complete response (CR) and partial response (PR)] is only ~ 50%, which means that half of the patients will receive treatment with no substantial clinical benefit.

Today, there is no single biomarker that can be used to predict response/resistance to chemotherapy in metastatic colorectal cancer patients (1). As most types of conventional chemotherapy kill cancer cells by inducing apoptosis, it could be hypothesized that markers of apoptosis protection would be useful as markers of chemotherapy resistance.

The proteases inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1), inhibits, in addition to its matrix metalloproteinase inhibitory function, apoptosis (2–5).

We and others have shown that plasma levels of TIMP-1 in patients with primary colorectal cancer are associated with patient outcome; that is, high plasma TIMP-1 predicts shorter patient survival (6–12). One explanation to this association is

---

Authors’ Affiliations: ¹Section of Biomedicine, Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Copenhagen, Denmark; ²Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; ³Department of Surgical Gastroenterology, Hvidovre University Hospital, Hvidovre, Denmark; and ⁴Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; 5Department of Surgical Gastroenterology, Hvidovre University Hospital, Hvidovre, Denmark; and ⁴Department of Oncology, Radiology and Pathobiology, Faculty of Life Sciences, University of Copenhagen, Copenhagen, Denmark.

Note: The results of this study were presented at the 2006 AACR Meeting as a poster.

Requests for reprints: Nils Brünner, Section of Biomedicine, Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Ridebanevej 3, 1870 Frederiksberg, Denmark. Phone: 45-26144708; Fax: 45-35353514; E-mail: nbr@life.ku.dk.

© 2007 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-07-0186

---

⁵www-dep.icrf.fr
that TIMP-1 protects cancer cells against the apoptotic stimuli that constitutively affect the cells. In support of an antiapoptotic function of TIMP-1, we have recently shown that in a cohort of 173 patients with metastatic breast cancer, high tumor tissue levels of TIMP-1 were highly significantly associated with chemotherapy resistance (13). For example, in patients with high tumor tissue TIMP-1 levels, the objective response (CR and PR) to chemotherapy was 0%. In accordance with these findings, Lipton et al. (14) showed that high plasma TIMP-1 was significantly associated with resistance to the antiestrogen tamoxifen in patients with metastatic breast cancer.

Based on the current knowledge of TIMP-1 as a protector of cancer cell apoptosis, we raised the hypothesis that levels of plasma TIMP-1 in patients with metastatic colorectal cancer would be predictive of response to chemotherapy. Indeed, the present study, including a homogeneous group of previously untreated patients treated with combination chemotherapy within a prospective trial, supports our hypothesis because a highly significant correlation was found between these two variables.

Patients and Methods

Patients and treatment. The study included 90 patients diagnosed with metastatic colorectal cancer. The study was done on a subpopulation of a larger study, NORDIC VI, a randomized phase III Nordic multicenter trial with 567 included patients comparing irinotecan in combination with either the Nordic bolus 5-fluorouracil (5-FU) and folinic acid schedule or the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer. All patients in two of the centers, Karolinska University Hospital (Stockholm, Sweden) and Akademiska Hospital (Uppsala, Sweden), were consecutively asked if they accepted the additional blood samples required in the study. In these two centers, 122 patients were randomized to the main study and 90 accepted the extra investigations on the blood samples. Of these, 87 were evaluable for objective response to chemotherapy.

Of the 90 patients, 77 had liver metastases, 23 lung metastases, 9 lymph node metastases, and 11 patients had multiple metastases.

Eligibility criteria included histologically proven adenocarcinoma of colon or rectum with metastatic disease, age between 18 and 75 years, no prior chemotherapy or only adjuvant chemotherapy if terminated >6 months before randomization was accepted, performance status (WHO) of 0 to 2, and at least one measurable metastatic lesion according to the Response Evaluation Criteria in Solid Tumors (15).

Written informed consent was obtained for all patients. Exclusion criteria included central nervous system metastases, current infection, diabetes, unresolved bowel obstruction, uncontrolled inflammatory bowel disease, current history of chronic diarrhea, or any other serious medical condition.

According to the study protocol, patients were randomized to receive either of the following treatments:

Arm A. Irinotecan: 180 mg/m² as a 30 to 90 min i.v. infusion on day 1 every 2 weeks immediately followed by 5-FU: 500 mg/m² i.v. bolus on days 1 and 2 every 2 weeks, followed 30 to 40 min later by folinic acid: 60 mg/m² i.v. bolus on days 1 and 2 every 2 weeks.

Arm B. Irinotecan: 180 mg/m² as a 30 to 90 min. i.v. infusion day 1 every 2 weeks, followed by folinic acid: 200 mg/m² as a 2 h i.v. infusion, days 1 and 2 every 2 weeks, followed by 5-FU: 400 mg/m² i.v. bolus followed by 600 mg/m² 5-FU as a 22 h i.v. infusion days 1 and 2 every 2 weeks.

Response evaluation. The primary efficacy variable was TTP defined as the time from randomization to the first documented progression or death due to progression. The secondary efficacy variable was overall survival (OS) calculated from the date of randomization until death. Responses were evaluated after every fourth cycle or every 2nd month if treatment was terminated. Treatment continued until progression or severe toxicity was noted. Overall response rate was defined as CR and PR as it is defined according to the Response Evaluation Criteria in Solid Tumors (15).

TIMP-1 analyses. EDTA plasma samples were drawn before start of chemotherapy. The samples were stored at -80°C until analyzed. In addition, in 75 of the patients, plasma samples were collected at 2, 4, and 6 weeks of treatment (samples were drawn before the initiation of each cycle). As previously described, plasma levels of TIMP-1 were determined by use of an established, validated TIMP-1 ELISA (6). In brief, for measurements of TIMP-1 protein levels, microtiter plates were coated with a sheep polyclonal antibody and detection of bound TIMP-1 (free and complex-bound forms) was done by use of a monoclonal antibody (MAC 15) and a secondary alkaline phosphatase–coupled antibody (DAKO). Readings of color development were taken every 10 min for 1 h, and calculations of concentrations were based on included recombinant TIMP-1 protein standards.

Carcinoembryonic antigen analyses. Serum samples were drawn before start of chemotherapy and after 2, 4, and 8 to 10 weeks of treatment. The level of carcinoembryonic antigen (CEA) was measured using the immunometric assay from Diasorin.

Statistics. Descriptive statistics are presented by the median and range. Tests for location were done using the Wilcoxon rank sum test or the Kruskal-Wallis test and the Spearman rank correlation was used as a measure of association. Covariates are either dichotomized by their median or entered by the actual value on the log scale (natural). Survival probabilities for time to progression (TTP) and OS are estimated by the Kaplan-Meier method and tests for differences between strata are done using the log-rank statistics. Analyses of TTP and OS for continuous covariates as well as multivariate analyses are done using the Cox proportional hazards model. The estimation of the probability of response is done using logistic regression analysis and results are presented using the odds ratio (OR) and the receiver operating characteristic curve, including the area under the curve. P values <5% are considered statistically significant. All calculations are done using SAS (version 9.1, SAS Institute).

Results

Levels of plasma TIMP-1 and association with baseline variables. All plasma samples contained measurable levels of TIMP-1. The median concentration was 121.9 ng/mL (range, 20.2-1,001.4 ng/mL) of plasma. The 95 percentile was 169.2 ng/mL of TIMP-1. Associations between plasma TIMP-1 and baseline variables are given in Table 1. Plasma TIMP-1 values were significantly associated with performance status (P = 0.003). In addition, TIMP-1 marginally associated with adjuvant treatment (P = 0.049); high TIMP-1 levels were found in those patients who had not received adjuvant treatment. No significant associations were seen between plasma TIMP-1 and age (r = 0.16, P = 0.12), gender (P = 0.36), location of the cancer (colon or rectum; P = 0.69), or allocated treatment (P = 0.92).

Levels of plasma TIMP-1 and serum CEA and association with best objective response. Eighty-seven patients were evaluable for response. Analysis of best objective response was scored as CR or PR versus stable disease (SD) or progressive disease (PD). Four patients obtained CR, 36 PR, 38 SD, and 9 PD. Of the 38 SD patients, eight had duration of SD <4 months. When TIMP-1 was treated as a continuous variable, the univariable analyses showed that patients with high plasma TIMP-1 had higher probability of no response [SD or PD; OR, 3.5; 95%
confidence interval, (95% CI), 1.4-8.5; \( P = 0.007 \). The area
under the curve was 0.67. Using the median TIMP-1 levels to
dichotomize the patients showed that among the 44 patients
with low TIMP-1, 26 (59%; 95% CI, 44-74%) obtained CR
or PR, whereas among the 43 patients with high plasma
TIMP-1, only 14 (33%; 95% CI, 19-47%) obtained an objective
response. Stratifying patients with SD by duration of response
showed that among the eight patients with SD <4 months,
seven (88%) had plasma TIMP-1 levels above the median.

Plasma TIMP-1 scored as a continuous covariate on the log
scale entered into a multivariate logistic regression analysis
showed that only TIMP-1 was a significant predictor of no
response (SD and PD; OR, 3.6; 95% CI, 1.4-9.5;
\( P = 0.001 \); Table 2). The OR for a patient with TIMP-1 level equal to the
3rd quartile of TIMP-1 levels compared with one with TIMP-1
equal to the 1st quartile was 2.4 (95% CI, 1.2-4.6).

Serum CEA levels were available for 67 of the 87 patients.
The median CEA level was 56 units/mL, ranging from 1 to
4,073. The rank correlation between CEA and TIMP-1 was 0.31
(\( P = 0.01 \)). This subset of patients is similar to the entire data
set with respect to the distribution of the clinical covariates, age,
and TIMP-1 levels. CEA treated as a continuous variable was a
significant predictor of no response (OR, 1.3; 95% CI, 1.0-1.7;
\( P = 0.02 \); area under the curve 0.66). Combining CEA with
TIMP-1 did not result in a significantly improved fit; the \( P \)
value to include CEA in a model with TIMP-1 was 0.09.

Levels of plasma TIMP-1 and serum CEA and association with
TTP and OS. Ninety patients were evaluable for TTP and OS.
There was a significant trend between TTP [hazard ratio (HR),
1.5; 95% CI, 1.0-2.3; \( P = 0.048 \)] and plasma TIMP-1 scored as a
continuous variable on the log scale (log \(_e\)). Kaplan-Meier
estimates of TTP are shown in Fig. 1 with TIMP-1 dichotomized
by the median. The figure illustrates that patients with plasma
TIMP-1 levels below the median have a significantly longer TTP
(HR, 1.9; 95% CI, 1.2-3.0; \( P = 0.01 \)) than patients with plasma
TIMP-1 above the median. The results of a multivariate analysis
including TIMP-1 and TTP are shown in Table 3. TIMP-1 is not
significant at the 5% level (\( P = 0.06 \)); however, TIMP-1 is the
only covariate close to statistical significance and model
selection results in TIMP-1 being the only covariate showing
statistical significance.

When testing for an association between plasma TIMP-1
scored as a continuous variable on the log scale (log \(_e\)) and OS, a
significant association between these two variables was found
(HR, 3.8; 95% CI, 2.4-5.9; \( P < 0.0001 \)). Kaplan-Meier estimates of OS
dichotomizing plasma TIMP-1 by its median level are shown in Fig. 2. As seen from this figure, there was a highly
statistically significant difference in OS between patients with
low versus high plasma TIMP-1 levels (HR, 4; 95% CI, 2.2-7.3;
\( P < 0.0001 \)). At time point 24 months, 16 patients were still
at risk in the low TIMP-1 group whereas only two patients were
at risk in the high TIMP-1 group. The survival probability at 24
months was 62% (95% CI, 46-77%) for patients with plasma
TIMP-1 below the median level and 7% (95% CI, 0-17%) for
those with TIMP-1 levels above the median. Multivariate
analysis showed (Table 4) that plasma TIMP-1 was significant

<table>
<thead>
<tr>
<th>Covariate</th>
<th>( N = 90 )</th>
<th>Association to TIMP-1</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized to FLIRI</td>
<td>44</td>
<td>0.92</td>
<td></td>
</tr>
<tr>
<td>FOLFIRI</td>
<td>46</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>60</td>
<td>0.36</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Localization</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon</td>
<td>59</td>
<td>0.69</td>
<td></td>
</tr>
<tr>
<td>Rectum</td>
<td>31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Performance status WHO</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>69</td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjuvant therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>79</td>
<td>0.049</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age median (min, max; y)</td>
<td>60 (36-75)</td>
<td>0.16*</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: FLIRI, Nordic bolus 5-FU and folinic acid schedule; FOLFIRI, bolus/infused de Gramont schedule.
* Spearman rank correlation (\( P = 0.12 \)).

Table 1. Associations between plasma TIMP-1 and baseline covariates

Table 2. Multivariate logistic regression analysis of no response (SD and PD) to chemotherapy

<table>
<thead>
<tr>
<th>Covariate</th>
<th>( P )</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized to FLIRI</td>
<td>0.54</td>
<td>1.3 (0.5-3.5)</td>
</tr>
<tr>
<td>FOLFIRI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>0.52</td>
<td>1.4 (0.5-3.7)</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Localization</td>
<td>0.76</td>
<td>1.6 (0.6-4.2)</td>
</tr>
<tr>
<td>Colon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rectum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Performance status WHO</td>
<td>0.81</td>
<td>0.9 (0.3-2.8)</td>
</tr>
<tr>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 + 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjuvant therapy</td>
<td>0.84</td>
<td>0.9 (0.2-3.4)</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>0.60</td>
<td>1.01 (0.96-1.07)</td>
</tr>
<tr>
<td>TIMP-1 ( \log_e )</td>
<td>0.001</td>
<td>3.6 (1.4-9.5)</td>
</tr>
</tbody>
</table>

Table 2. Multivariate logistic regression analysis of no response (SD and PD) to chemotherapy

www.aacrjournals.org ClinCancerRes 2007;13(14) July 15, 2007

Fig. 1. Kaplan-Meier curves showing the association between plasma TIMP-1 values and TTP. The number of events (progressions) and number of patients at risk at different time points during the observation period for each of the two groups are given below the figure. Solid line, patients with plasma TIMP-1 levels below the median; broken line, patients with plasma TIMP-1 levels above the median.
for OS when including routine clinical baseline covariates (HR, 3.5; 95% CI, 2.1-5.8; \( P < 0.0001 \)). The only other significant covariate for OS was performance score (HR, 2.4; 95% CI, 1.2-4.5; \( P = 0.008 \)). In a multivariable analysis now including TTP instead of OS, plasma TIMP-1 and baseline covariates showed that only plasma log TIMP-1 treated as a continuous variable was retained in the model (HR, 1.5; 95% CI, 1.0-2.3; \( P = 0.049 \)).

Assessment of CEA used as a continuous variable on the log scale for the analysis of TTP and OS showed that this model formulation was inappropriate (not linear on a log scale). CEA scale for the analysis of TTP and OS showed that this model formulation was inappropriate (not linear on a log scale). CEA was not a significant predictor of TTP (\( n = 68, P = 0.56 \)) using the conventional cutpoint of 5 units/mL. Nor was CEA a significant predictor of OS (\( P = 0.56 \)) in a model also including TIMP-1.

Discussion

The present study shows that high plasma levels of TIMP-1 in patients with metastatic colorectal cancer treated with first-line combination chemotherapy are indicative of low probability of objective response to chemotherapy. This decreased probability of obtaining an objective response to chemotherapy in plasma high TIMP-1 patients was reflected in a significantly decreased TTP and OS of these patients. Based on the present results, it is, however, not possible to clearly separate the effect of TIMP-1 on prognosis (6-12) or on objective response to chemotherapy.

The possibility to predict response to chemotherapy in metastatic colorectal cancer has wide implications as it is anticipated that presently only \( \sim 50\% \) of metastatic colorectal cancer patients receiving chemotherapy have clear benefit thereof. A predictive biomarker could thus be used to protect patients from ineffective treatment and thereby from the adverse effects induced by chemotherapy. On the other hand, the predictive biomarker could be used to select metastatic colorectal cancer patients not only for routine systemic chemotherapy, but also for clinical trials testing either different or more aggressive treatment schedules, or new types of chemotherapy/biological–based therapy.

In the present study, the patients received irinotecan and 5-FU + folinic acid by two different schedules. The treatment schedule was not retained in the multivariate analysis, suggesting that the association between plasma TIMP-1 and objective response was independent of treatment schedule but directly related to tumor sensitivity/resistance to the drugs. Analyses of the entire randomized study of 557 patients reveal that there is no difference between schedules for either TTP or OS.\(^6\) The question then arise whether the present results are only valid when these two drugs are being used or whether plasma TIMP-1 would also predict sensitivity/resistance to other classes of chemotherapeutic compounds. We have recently found that patients with metastatic breast cancer and high tumor tissue levels of TIMP-1 in the tumor tissue sampled at the time of primary surgery are resistant to systemic chemotherapy, either the combinations of cyclophosphamide, methotrexate and 5-FU, cyclophosphamide, epirubicin and 5-FU, or doxorubicin given alone (13). Taking these data together with the present findings suggest that TIMP-1 predicts for sensitivity/resistance to several classes of chemotherapy. The strong associations with both TTP, directly related to the efficacy of the first-line combination, and OS, influenced also by the efficacy of subsequent lines of treatment, suggest that the predictive ability is not restricted to the used combination. In further support of this statement is that in our experimental model consisting of wild-type and TIMP-1 gene-deficient fibrosarcoma cells (16), we consistently find the TIMP-1–expressing wild-type cells more resistant than the TIMP-1 gene-deficient cells to a variety of chemotherapeutic compounds (etoposide, vincristine, and Cytosar).

CEA levels were also measured in a subset of the patients (\( n = 67 \)). CEA treated as a continuous variable was found to be significantly associated with objective response, with higher serum CEA levels predicting lack of objective response. However, when combining CEA with TIMP-1, no significantly improved fit was obtained. Serum CEA was neither a significant predictor of TTP nor of OS when TIMP-1 was included as the only other covariate.

The antiapoptotic effect of TIMP-1 can be regulated both in a matrix metalloproteinase (MMP)–dependent and a MMP-independent way. In vivo and in vitro experiments, using

---

\(^6\) B. Glimelius et al., unpublished information.

### Table 3. Multivariate Cox regression analysis of TTP

<table>
<thead>
<tr>
<th>Covariate</th>
<th>( P )</th>
<th>HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized to FLIRI</td>
<td>0.33</td>
<td>1.3 (0.8-2.1)</td>
</tr>
<tr>
<td>FOLFIRI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>0.33</td>
<td>0.8 (0.5-1.3)</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Localization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon</td>
<td>0.20</td>
<td>0.7 (0.4-1.2)</td>
</tr>
<tr>
<td>Rectum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Performance status WHO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0.68</td>
<td>1.1 (0.6-2.0)</td>
</tr>
<tr>
<td>1 + 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjuvant therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>0.54</td>
<td>1.3 (0.6-2.8)</td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>0.31</td>
<td>1.0 (0.96-1.01)</td>
</tr>
<tr>
<td>TIMP-1 loge</td>
<td>0.06</td>
<td>1.5 (1.0-2.3)</td>
</tr>
</tbody>
</table>

Fig. 2. Kaplan-Meier curves showing the association between plasma TIMP-1 values and OS. The number of events (disease related deaths) and number of patients at risk at different time points during the observation period for each of the two groups are given below the figure. Solid line, patients with plasma TIMP-1 levels below the median; broken line, patients with plasma TIMP-1 levels above the median.
mammary epithelial cells, have shown that apoptotic effector molecules, such as caspasases, are induced by degradation of the extracellular matrix by MMPs, leading to apoptotic cell death (2–4). As such, the anti-MMP function of TIMP-1 would indirectly inhibit apoptosis. In support of this notion is the study of a apoptosis in mammary epithelial cells originating from MMP-3 transgenic mice showing that the number of apoptotic cells was significantly reduced when the cells came from MMP-3 transgenic/TIMP-1–overexpressing mice (4). In support of an MMP-independent TIMP-1 antia apoptotic function is that reduced or alkylated TIMP-1, completely devoid of all MMP inhibitory activity, effectively inhibits apoptosis in Burkitt’s lymphoma cells (5). In the same study, it was also reported that addition of recombinant TIMP-1 lead to inhibition of apoptosis, and that addition of anti–TIMP-1 antibodies to neutralize secreted TIMP-1 resulted in a 4-fold increase in induction of apoptosis. The antia apoptotic mechanism of TIMP-1 could be mediated by interaction with a binding protein, which may induce survival signals through activation of the focal adhesion kinase and/or the phosphati dylinositol 3-kinase, leading to increased expression of the antiapoptotic protein Bcl-XL and preventing activation of the caspase cascade (17–20). Indeed, it was recently reported that TIMP-1 binds to CD63, which is a membrane protein belonging to the family of teraspan molecules (21). Added TIMP-1 was shown to bind to cell surfaces, inducing activation of the above-described signaling pathway leading to protection of the cells from apoptotic stimuli.

Knowing that TIMP-1 can induce chemoresistance in cancer cells in vitro, it is obvious to speculate whether TIMP-1 could represent a valid target for increasing tumor cell sensitivity to chemotherapy. Normal cells do not overexpress TIMP-1, and the TIMP-1 gene–deficient mouse is without any detectable phenotype, suggesting that systemic inhibition of TIMP-1 in a patient, who subsequently receives chemotherapy, would not induce additional toxicity in the normal tissue. We have recently published that also another proteinase inhibitor, plasminogen activator inhibitor-1, protects cancer cells against apoptosis induced by a wide range of chemotherapeutic compounds (22, 23). Of particular interest was that although PAI-1 gene–deficient murine fibrosarcoma cells showed increased sensitivity to chemotherapy in vitro, no difference in systemic toxicity was observed when exposing PAI-1 gene–deficient and wild-type mice to chemotherapy.

The present study was done on plasma. We believe that the elevated plasma TIMP-1 found in the metastatic colorectal cancer patients originates from the metastatic tumor tissue and thereby reflects production and secretion of TIMP-1 from the tumor tissue. It could thus be of interest to test whether tumor tissue TIMP-1 instead of plasma TIMP-1 measurements would give a more direct TIMP-1 tumor measurement and thereby superior results regarding drug sensitivity/resistance. It is noteworthy that the data obtained in our breast cancer study originated from tumor tissue TIMP-1 measurements from the primary tumor (13).

Future studies should be designed to determine clinically relevant cutpoints of plasma TIMP-1 and further prospectively validate plasma TIMP-1 measurements in the prediction of response to chemotherapy in patients with metastatic colorectal cancer. Future studies should also include measurements of other potential predictive markers in addition to TIMP-1 to determine if any other biomarker should be included together with TIMP-1 in a panel of markers to be used to predict sensitivity/resistance to chemotherapy in patients with metastatic colorectal cancer.

**Table 4. Multivariate Cox regression analysis of OS**

<table>
<thead>
<tr>
<th>Covariate</th>
<th>P</th>
<th>HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized to FLIRI FOLFIRI</td>
<td>0.30</td>
<td>1.4 (0.8-2.4)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>0.87</td>
<td>0.9 (0.5-1.6)</td>
</tr>
<tr>
<td>Female</td>
<td>0.74</td>
<td>0.7 (0.4-1.4)</td>
</tr>
<tr>
<td>Localization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon</td>
<td>0.008</td>
<td>2.4 (1.2-4.5)</td>
</tr>
<tr>
<td>Rectum</td>
<td>0.30</td>
<td>1.8 (0.6-5.4)</td>
</tr>
<tr>
<td>Age (y)</td>
<td>0.78</td>
<td>1.00 (0.96-1.03)</td>
</tr>
<tr>
<td>TIMP-1 loge</td>
<td>&lt;0.0001</td>
<td>3.5 (2.1-5.8)</td>
</tr>
</tbody>
</table>

**References**


